Organon & Co. (NYSE:OGN) Shares Purchased by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. grew its holdings in shares of Organon & Co. (NYSE:OGN) by 105.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,713 shares of the company’s stock after purchasing an additional 16,247 shares during the period. Stratos Wealth Partners LTD.’s holdings in Organon & Co. were worth $473,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in OGN. Barclays PLC increased its stake in Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after buying an additional 84,136 shares during the period. Weiss Asset Management LP acquired a new position in shares of Organon & Co. in the third quarter worth $32,966,000. Cerity Partners LLC increased its position in shares of Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after acquiring an additional 323,308 shares during the period. Foundry Partners LLC acquired a new stake in shares of Organon & Co. in the third quarter valued at $7,642,000. Finally, Beddow Capital Management Inc. raised its stake in shares of Organon & Co. by 38.8% in the third quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after acquiring an additional 85,775 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $21.33.

Organon & Co. Trading Down 0.5 %

NYSE OGN opened at $14.96 on Wednesday. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The firm has a 50 day moving average of $15.34 and a two-hundred day moving average of $17.56. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock has a market capitalization of $3.85 billion, a PE ratio of 2.97, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.